|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: AK8 |
Gene summary for AK8 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | AK8 | Gene ID | 158067 |
| Gene name | adenylate kinase 8 | |
| Gene Alias | AK 8 | |
| Cytomap | 9q34.13 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q96MA6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 158067 | AK8 | C38 | Human | Oral cavity | OSCC | 3.10e-09 | 7.54e-01 | 0.172 |
| 158067 | AK8 | C43 | Human | Oral cavity | OSCC | 8.17e-12 | 2.93e-01 | 0.1704 |
| 158067 | AK8 | LN38 | Human | Oral cavity | OSCC | 1.54e-03 | 6.14e-01 | 0.168 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000675318 | Oral cavity | OSCC | nucleoside phosphate metabolic process | 247/7305 | 497/18723 | 6.28e-07 | 8.96e-06 | 247 |
| GO:000911719 | Oral cavity | OSCC | nucleotide metabolic process | 243/7305 | 489/18723 | 7.80e-07 | 1.09e-05 | 243 |
| GO:00091233 | Oral cavity | OSCC | nucleoside monophosphate metabolic process | 50/7305 | 76/18723 | 2.04e-06 | 2.62e-05 | 50 |
| GO:000913217 | Oral cavity | OSCC | nucleoside diphosphate metabolic process | 70/7305 | 124/18723 | 6.03e-05 | 4.95e-04 | 70 |
| GO:004693917 | Oral cavity | OSCC | nucleotide phosphorylation | 58/7305 | 101/18723 | 1.33e-04 | 9.44e-04 | 58 |
| GO:000616517 | Oral cavity | OSCC | nucleoside diphosphate phosphorylation | 56/7305 | 99/18723 | 2.95e-04 | 1.85e-03 | 56 |
| GO:19012938 | Oral cavity | OSCC | nucleoside phosphate biosynthetic process | 125/7305 | 256/18723 | 8.32e-04 | 4.41e-03 | 125 |
| GO:00091658 | Oral cavity | OSCC | nucleotide biosynthetic process | 124/7305 | 254/18723 | 8.79e-04 | 4.63e-03 | 124 |
| GO:000914119 | Oral cavity | OSCC | nucleoside triphosphate metabolic process | 58/7305 | 112/18723 | 4.01e-03 | 1.64e-02 | 58 |
| GO:0021591 | Oral cavity | OSCC | ventricular system development | 18/7305 | 29/18723 | 1.00e-02 | 3.49e-02 | 18 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa012404 | Oral cavity | OSCC | Biosynthesis of cofactors | 88/3704 | 153/8465 | 3.84e-04 | 1.20e-03 | 6.12e-04 | 88 |
| hsa0124011 | Oral cavity | OSCC | Biosynthesis of cofactors | 88/3704 | 153/8465 | 3.84e-04 | 1.20e-03 | 6.12e-04 | 88 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| AK8 | SNV | Missense_Mutation | novel | c.72N>G | p.Phe24Leu | p.F24L | Q96MA6 | protein_coding | deleterious(0) | benign(0.168) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| AK8 | SNV | Missense_Mutation | c.647N>A | p.Ala216Asp | p.A216D | Q96MA6 | protein_coding | tolerated(0.11) | benign(0.372) | TCGA-E2-A15S-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| AK8 | insertion | Nonsense_Mutation | novel | c.308_309insAGGGTAGGGGAGGAGAAG | p.Ala103_Arg104insGlyTerGlyArgArgSer | p.A103_R104insG*GRRS | Q96MA6 | protein_coding | TCGA-A2-A0EX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| AK8 | insertion | Frame_Shift_Ins | novel | c.307_308insGAGGGGGA | p.Ala103GlyfsTer22 | p.A103Gfs*22 | Q96MA6 | protein_coding | TCGA-A2-A0EX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| AK8 | deletion | Frame_Shift_Del | novel | c.1316delN | p.Asn439ThrfsTer73 | p.N439Tfs*73 | Q96MA6 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| AK8 | SNV | Missense_Mutation | c.547N>G | p.Gln183Glu | p.Q183E | Q96MA6 | protein_coding | tolerated(0.41) | benign(0.02) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| AK8 | SNV | Missense_Mutation | c.558G>C | p.Glu186Asp | p.E186D | Q96MA6 | protein_coding | tolerated(0.58) | benign(0.031) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| AK8 | SNV | Missense_Mutation | rs375128507 | c.1016G>A | p.Arg339His | p.R339H | Q96MA6 | protein_coding | deleterious(0.03) | benign(0.429) | TCGA-VS-A8EI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| AK8 | SNV | Missense_Mutation | rs750120409 | c.589N>A | p.Glu197Lys | p.E197K | Q96MA6 | protein_coding | tolerated(0.07) | benign(0.369) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| AK8 | SNV | Missense_Mutation | novel | c.1147N>T | p.Asp383Tyr | p.D383Y | Q96MA6 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |